Please assess the completion status of the following clinical trial:

Trial Title: An Efficacy and Safety Study of MORAb-003 in Platinum-Resistant or Refractory Relapsed Ovarian Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of non-mucinous epithelial ovarian cancer, including primary peritoneal and fallopian tube malignancies, measurable by CT or MRI scan assessed within 4 weeks prior to study entry~* Must have evidence of relapse by CA-125 (2xUpper Limit of Normal) or radiographically within 6 months of most recent platinum-containing chemotherapy. At least one of the lines of chemotherapy must have included a taxane.~* Must have been treated with debulking surgery and at least one line platinum-based chemotherapy;~* Subjects may have received up to four additional lines of chemotherapy after they developed platinum-resistance.~* Subjects must be candidate for repeat paclitaxel treatment~Exclusion Criteria:~* Clinical contraindications to use of paclitaxel, which include:~  1. persistent Grade 2 or greater peripheral neuropathy~ 2. prior hypersensitivity reaction that persisted despite rechallenge with or without desensitization or resulted in bronchospasm or hemodynamic instability or was at least Grade 2 and resulted in medication discontinuation~* Current diagnosis of epithelial ovarian tumor of low malignant potential (borderline carcinomas). Note: EOC with prior diagnosis of a low malignant potential tumor that has been surgically resected is acceptable provided the subject did~* Prior radiation therapy is excluded with the exception that it is allowable only if measurable disease for ovarian cancer is completely outside the radiation portal~* Known allergic reaction to a prior monoclonal antibody therapy or have any documented human anti-human antibody (HAHA).~* Previous treatment with MORAb-003 (farletuzumab).

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): MORAb-003 (Farletuzumab) Plus Paclitaxel
- 2 (Type: PLACEBO_COMPARATOR): Placebo Plus Paclitaxel

Based on this trial design, predict the completion outcome and termination type (if applicable).